Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9353539 | 0.78 | MTNR1A (0.42) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL43675 | 0.78 | MTNR1A (0.42) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL312762 | 0.73 | ATM (0.40) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL7661580 | 0.73 | LTA4H (0.39) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL7417657 | 0.71 | MTNR1A (0.43) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL947518 | 0.71 | CA4 (0.41) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL1231285 | 0.71 | KDM4E (0.41) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL5092064 | 0.71 | ANPEP (0.41) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL57754 | 0.70 | MTNR1A (0.46) | MTNR1AMTNR1BGAACYP1A2CYP2C9 | |
| SCHEMBL11156032 | 0.70 | CA4 (0.43) | MTNR1AMTNR1BGAACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341479-A1 | LNA-G PROCESS | Roche Innovation Center Copenhagen A/S (DK) | 2018-07-04 | — | — | EP | claimed |
| WO-2017032726-A1 | LNA-G PROCESS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-03-02 | — | — | WO | claimed |
| EP-2928877-A1 | DISULFIDE MASKED PRODRUG COMPOSITIONS AND METHODS | Merck Sharp & Dohme Corp. (US) | 2015-10-14 | — | — | EP | claimed |
| WO-2014088920-A1 | DISULFIDE MASKED PRODRUG COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2303905-B1 | CHEMICAL RNA SYNTHESIS METHOD | CENTRE NAT RECH SCIENT (FR) | 2012-11-28 | — | — | EP | claimed |
| US-8076461-B2 | antibody microarray for detecting incomplete deprotection of synthetic test oligonucleotides; high throughput assay; solid phase synthesis | PROTEOME SCIENCES PLC (GB) | 2011-12-13 | — | — | US | claimed |
| US-20110275793-A1 | Chemical RNA Synthesis Method | CHEMGENES CORPORATION | 2011-11-10 | — | — | US | claimed |
| EP-1412752-B1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI Q INC (US) | 2011-06-22 | — | — | EP | claimed |
| JP-4500540-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| US-20090048436-A1 | Methods of synthesizing chemically cleavable phosphoramidite linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
| US-20090047712-A1 | Chemically cleavable phosphoramidite linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
| JP-2005517897-A | — | — | 2005-06-16 | — | — | JP | claimed |
| EP-1412752-A4 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI Q INC (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040185476-A1 | Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids | VERI-Q, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2003003014-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI Q INC (US) | 2004-05-13 | — | — | WO | claimed |
| EP-1412752-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003039523-A2 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES | EXIQON A/S (DK) | 2003-05-15 | — | — | WO | claimed |
| WO-2003003014-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| US-20240191276-A1 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-06-13 | — | — | US | disclosed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275793-A1 | Chemical RNA Synthesis Method | NSUN3, POLR2E, POLR2H | MTNR1A 3393/4885MTNR1B 3871/4885GAA 4543/4885 |
| US-20090047712-A1 | Chemically cleavable phosphoramidite linkers | CPSF6, RNGTT, CPSF1 | MTNR1A 4365/4885MTNR1B 4572/4885GAA 607/4885 |
| US-20090048436-A1 | Methods of synthesizing chemically cleavable phosphoramidite linkers | RNGTT, CPSF6, CPSF1 | MTNR1A 4388/4885MTNR1B 4539/4885GAA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.